Evidence map›Paper›PMID 10906198›Full record

ArticleJournal of virology2000

The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency.

L F van Dyk, H W Virgin, S H Speck

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 120 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Host Tumor Suppressor p18Journal of virology · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

L F van DykDepartment of Pathology and Immunology and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
H W Virgin
S H Speck
Washington University in St. Louis · US

Funding

TRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8M
Control of Gammaherpesvirus ReplicationR01CA052004 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 1990 to 2013
$4.1M
Regulation of Y-herpesvirus latency and tumorigenesisR01CA074730 · NCI · WASHINGTON UNIVERSITY · PI VIRGIN, HERBERT W · 1998 to 2007
$2.8M
Vascular Injury and Atherosclerosis During Herpesvirus *R01HL060090 · NHLBI · WASHINGTON UNIVERSITY · PI VIRGIN, HERBERT W · 1999 to 2005
$2.5M
REGULATION OF EBV TRANSCRIPTION IN BURKITTS LYMPHOMAR01CA058524 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 1995 to 2009
$2.4M
VIRAL TRANSCRIPTION IN EBV TRANSFORMED HUMAN B CELLSR01CA043143 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 1986 to 2006
$1.7M
NCI NIH HHS CA43143NCI NIH HHS CA52004NCI NIH HHS CA58524NCI NIH HHS R01 CA043143NCI NIH HHS R01 CA052004NCI NIH HHS R01 CA058524NCI NIH HHS R01 CA074730NHLBI NIH HHS R01 HL060090NIAID NIH HHS T32 AI007163
6 · The paper itself

Abstract

Gamma-2 herpesviruses encode a homolog of mammalian D-type cyclins. The v-cyclin encoded by murine gammaherpesvirus 68 (gammaHV68) induces cell cycle progression and is an oncogene (L. F. van Dyk, J. L. Hess, J. D. Katz, M. Jacoby, S. H. Speck, and H. W. Virgin IV, J. Virol. 73:5110-5122, 1999). However, the role of the pro-proliferative v-cyclins in gamma-2 herpesvirus pathogenesis is not known. Here we report the generation and characterization of a gammaHV68 v-cyclin mutant (v-cyclin.LacZ) that is unable to express a functional v-cyclin protein. Notably, although the gammaHV68 v-cyclin is expressed from an early-late lytic transcript, v-cyclin. LacZ replicated normally in fibroblasts in vitro and during acute infection in the spleen, liver, and lungs in vivo. Moreover, v-cyclin.LacZ exhibited wild-type (wt) virulence in mice with severe combined immunodeficiency. In addition, in a model of gammaHV68-induced chronic disease in mice lacking the gamma interferon receptor (IFNgammaR(-/-)), v-cyclin.LacZ virus was similar to wt gammaHV68 in terms of the incidence of mortality and vasculitis. Further analysis revealed that the frequencies of splenocytes and peritoneal cells harboring the latent gammaHV68 genome in normal and B-cell-deficient mice infected with wt gammaHV68 or v-cyclin.LacZ were very similar. However, v-cyclin.LacZ was significantly compromised in its capacity to reactivate from latency. This phenotype was conclusively mapped to the v-cyclin gene by (i) generating a marker rescue virus (v-cyclin.MR) from the v-cyclin.LacZ mutant, which restored the frequency of cells in which virus reactivated from latency to the levels observed with wt gammaHV68; and (ii) generating a second v-cyclin mutant virus containing a translation stop codon within the v-cyclin gene (v-cyclin.stop), which was compromised in reactivation from latency. These studies demonstrate that despite expression as a lytic cycle gene, the pro-proliferative gammaHV68 v-cyclin is not required for gammaHV68 replication either in vitro or during acute infection in vivo but rather is a critical determinant of reactivation from latency.

Indexed as

Virus ActivationVirus LatencyAnimalsCells, CulturedCyclinsFibroblastsGammaherpesvirinaeGene Expression Regulation, ViralGene TargetingHerpesviridae InfectionsInterferon-gammaMiceMice, SCIDViral ProteinsVirulenceVirus ReplicationCyclinsInterferon-gammaViral Proteins

Identifiers

PMID10906198
PMCPMC112265
OpenAlexW2146375964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.